• Levemir®
  (insulin detemir [rDNA origin] injection)
• NovoLog®
  (insulin aspart [rDNA origin] injection)
• NovoLog® Mix 70/30
  (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])
• Novolin® N InnoLet®
  (NPH, human insulin isophane suspension [recombinant DNA origin])
• Novolin® R InnoLet®
  (regular, human insulin injection [recombinant DNA origin] USP)
• Novolin® 70/30 InnoLet®
  (70% NPH, human insulin isophane suspension and 30% regular, human insulin injection [recombinant DNA origin])
• Prandin®
  (repaglinide) tablets
• GlucaGen® HypoKit®
  (glucagon [rDNA origin] for injection)

• Home
• novonordisk-us.com
• Glossary
• Additional Resources
• Important Safety Information
• Prescribing Information

Novo Nordisk's Commitment to People with Diabetes

At Novo Nordisk, we know that our leadership in diabetes care must go beyond our products. That's why our approach has always been focused on patient-centered care. Our commitment to diabetes care will always remain our passion and our business.

Our portfolio of insulins and delivery systems is the result of over 80 years of diabetes innovation and leadership.